IRIS
RASI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.419
AS - Asia 3.923
EU - Europa 3.131
SA - Sud America 580
Continente sconosciuto - Info sul continente non disponibili 221
AF - Africa 47
OC - Oceania 8
Totale 36.329
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.245
SG - Singapore 1.978
CN - Cina 875
IT - Italia 597
BR - Brasile 480
UA - Ucraina 413
DE - Germania 399
RU - Federazione Russa 357
HK - Hong Kong 316
IE - Irlanda 282
PL - Polonia 265
FR - Francia 259
VN - Vietnam 249
GB - Regno Unito 163
SE - Svezia 133
KR - Corea 120
FI - Finlandia 116
JP - Giappone 115
CA - Canada 96
BD - Bangladesh 65
NL - Olanda 59
IN - India 52
AR - Argentina 34
MX - Messico 31
EC - Ecuador 20
UZ - Uzbekistan 20
AT - Austria 19
ID - Indonesia 18
ZA - Sudafrica 16
CO - Colombia 14
IQ - Iraq 14
ES - Italia 13
TR - Turchia 12
VE - Venezuela 12
IR - Iran 11
PH - Filippine 11
BE - Belgio 10
CL - Cile 10
PK - Pakistan 9
SA - Arabia Saudita 9
EU - Europa 8
JM - Giamaica 8
MA - Marocco 8
AU - Australia 7
EG - Egitto 7
IL - Israele 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
NI - Nicaragua 6
RO - Romania 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
HN - Honduras 5
LT - Lituania 5
MY - Malesia 5
CH - Svizzera 4
GT - Guatemala 4
KE - Kenya 4
KZ - Kazakistan 4
OM - Oman 4
PT - Portogallo 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
GR - Grecia 3
JO - Giordania 3
NG - Nigeria 3
PE - Perù 3
PY - Paraguay 3
SV - El Salvador 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
DM - Dominica 2
HU - Ungheria 2
LB - Libano 2
LV - Lettonia 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AI - Anguilla 1
BF - Burkina Faso 1
BG - Bulgaria 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
DZ - Algeria 1
EE - Estonia 1
GH - Ghana 1
GY - Guiana 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
LY - Libia 1
Totale 36.111
Salva come PNG Salva come JPEG
Città #
Woodbridge 7.568
Wilmington 7.097
Houston 5.921
Ashburn 834
Singapore 802
Ann Arbor 757
Fairfield 622
San Jose 469
Jacksonville 382
Chandler 355
Beijing 327
Hong Kong 307
Dublin 277
Kraków 251
Seattle 241
Medford 225
Cambridge 224
Dearborn 155
Council Bluffs 149
Santa Clara 144
The Dalles 122
Rome 120
Los Angeles 110
New York 101
Lawrence 99
Dallas 93
Tokyo 92
Hangzhou 78
Ho Chi Minh City 75
Zhengzhou 73
Buffalo 68
Hanoi 67
Mülheim 63
Milan 56
San Diego 51
São Paulo 51
Moscow 43
Lauterbourg 41
North Bergen 39
Porto Alegre 36
Chicago 33
Helsinki 32
Toronto 32
Boardman 30
London 25
Menlo Park 25
Brooklyn 24
Shanghai 24
Munich 22
Nuremberg 22
Atlanta 20
Haiphong 20
Falls Church 19
Hefei 19
University Park 18
Columbus 17
Frankfurt am Main 17
Nanjing 17
Orem 17
Verona 17
Chennai 16
Denver 16
Rio de Janeiro 16
Montreal 15
San Mateo 15
Bologna 14
Miami 14
Norwalk 14
Belo Horizonte 13
Redwood City 13
Yongsan-gu 13
Naples 12
San Francisco 12
Warsaw 12
Washington 12
Johannesburg 11
Kunming 11
Mountain View 11
Seoul 11
Boston 10
Brasília 10
Guayaquil 10
Detroit 9
Fukuoka 9
Guangzhou 9
Jakarta 9
Las Vegas 9
Tashkent 9
Brussels 8
Chengdu 8
City of London 8
Curitiba 8
Da Nang 8
Florence 8
Lansdale 8
Tampa 8
Amsterdam 7
Charlotte 7
Goiânia 7
Manchester 7
Totale 29.462
Salva come PNG Salva come JPEG
Nome #
Thymosin alpha 1: from bench to bedside 650
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies 595
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance 579
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 568
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 545
Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B 521
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1 515
ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS 514
Survivin-Igm Immuno Complex: A Novel Candidate Biomarker Of Cirrhosis To Monitor Patients Progression Towards Hepatocellular Carcinoma 508
Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety 498
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 497
Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling 495
TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. 487
The risks of risk aversion in drug regulation 481
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 479
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union 478
Combined treatment with thymosin-alpha 1 and low dose interferon-alpha after dacarbazine in advanced melanoma 473
Access to patient-level trial data--a boon to drug developers 473
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 466
Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B 465
Anti-tumour immunogens and vaccines 463
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling 461
Combination therapy with BRMs in cancer and infectious diseases 458
Treatment of aspergillus infection with thymosin alpha 1 457
Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy 455
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 454
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma 451
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis 448
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 446
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 445
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a 441
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation 441
Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo 438
Combination thymosin alpha(1) and lymphoblastoid interferon treatment in chronic hepatitis C 435
differentiation therapy: in vitro evidence making cyanidin-3-o--glucopiranoside useful for prevention and treatment of melanoma 432
An audience with Guido Rasi. Interview by Asher Mullard 432
up-regulation of melanocytic differentiation antigens induced by cyanidin-3-o--glucopyranoside in human melanoma cells. 430
comparative cellular signal patway analysis of metastatic colorectal cancer in human and preclinical animal model 427
nerve growth factor (ngf) and cirrhosis: a possible new marker of progression to hepatocellular carcinoma (hcc) 423
Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts 421
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 420
Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside 417
early detection of molecular markers suitable for colorectal cancer diagnosis and therapy in a carcinogenesis model 417
Influenza della concentrazione di adriamicina su modificazioni volumetriche e proliferazione di cellule leucemiche in vitro 417
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response 413
ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153 413
Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model 409
Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice 407
Straight talk with...Guido Rasi. Interview by Roxanne Khamsi 405
COMPARATIVE CELLULAR SIGNAL PATWAY ANALYSIS OF METASTATIC COLORECTAL CANCER IN HUMAN AND PRECLINICAL ANIMAL MODEL 403
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 401
Fifty years after thalidomide; what role for drug regulators? 398
Preclinical studies using oncofidä-s, a new sn38-hyaluronic acid bioconyugate, for cd44-targeted therapy of colon carcinoma 397
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee 397
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. 394
nerve growth factor (ngf): a possible marker for hepatocellular carcinoma (hcc)? 394
up-regulation of melan-a/mart-1 antigen expression during human melanoma cell differentiation 393
Method of up-regulating tumor antigen expression using thymalfasin 389
Characterization of four newly established melanoma cell lines 389
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery 388
preventive peptide vaccine for colorectal cancer metastases 387
null 385
null 380
Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms 377
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer 345
null 342
Rationale for therapeutic approaches with thymic hormones, interleukin 2 and interferon in combination with chemotherapy. 328
Stimolazione in vivo mediante prostaglandine ed interferone dell'attività natural killer in topi trattati con ciclofosfamide. vol. 87, p. 595-603 327
A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker 278
Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions 272
A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker 256
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A phase-II controlled trial 246
BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS 216
Sequential biochemotherapy for metastatic colorectal cancer using, fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects 207
Open clinical trial data for all? A view from regulators 204
Asthma, allergy and the olympics: A 12-year survey in elite athletes 191
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation 187
Clinical trial publications: A sufficient basis for healthcare decisions? 183
From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients 176
Expression profile of HERVs and inflammatory mediators detected in nasal mucosa as a predictive biomarker of COVID-19 severity 174
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 161
Big Data – How to Realize the Promise 158
Preliminary evidence of the differential expression of human endogenous retroviruses in Kawasaki disease and SARS-CoV-2-associated multisystem inflammatory syndrome in children 155
preventive peptide vaccine for colorectal cancer metastases 146
Innovative medicines: New regulatory procedures for the third millennium 143
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice 142
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? 141
Transparency and the European medicines agency - Sharing of clinical trial data 139
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves 139
First-in-human clinical trials - What we can learn from tragic failures 138
High CD169 monocyte/lymphocyte ratio reflects immunophenotype disruption and oxygen need in COVID-19 patients 138
Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward 136
European regulatory experience with drugs for central nervous system disorders 135
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations 134
Steps forward in regulatory pathways for acute and chronic heart failure 119
High CD169 Monocyte/Lymphocyte Ratio Reflects the Immunophenotyping Disruption and Predicts Oxygen Need in COVID-19 Patients 116
Drug regulation and pricing - Can regulators influence affordability? 115
Characterization of three melanoma cell lines (TVM-A12, TVM-A-197, TVM-BO): Sensitivity to lysis and effect of retinoic acid 110
Inhibitor of fatty acid amide hydrolase: learning from tragic failures [The editorialists reply] 109
[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).] 101
Totale 35.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.939
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.939
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022787 0 0 0 26 24 92 77 38 94 67 57 312
2022/20231.150 127 53 45 120 91 292 97 79 81 12 129 24
2023/2024317 40 8 31 18 30 67 11 11 2 11 13 75
2024/20252.991 69 585 319 136 51 223 121 145 256 245 441 400
2025/20263.762 320 173 449 256 334 101 416 539 447 430 157 140
2026/20271.783 213 222 824 524 0 0 0 0 0 0 0 0
Totale 36.329